Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Annkristin Heine

Showing results (1-10 of 65) with videos related to

Pageof 7
Sort By:
Blood|May 30, 2015
A party of three: iNKT cells in GVHD preventionAnnkristin Heine, Peter Brossart
Experimental Hematology|March 31, 2025
Establishing a low-dose x-ray irradiation protocol for experimental acute graft-versus-host diseaseMichelle Klesse, Oliver Schanz, Annkristin Heine
Oncoimmunology|May 7, 2014
Implementing combinatorial immunotherapeutic regimens against cancer: The concept of immunological conditioningDominik Wolf, Annkristin Heine, Peter Brossart
Trends in Cancer|July 24, 2024
Next-generation cancer vaccines and emerging immunotherapy combinationsAnne Brandenburg, Annkristin Heine, Peter Brossart
Molecular Cancer|March 16, 2021
Clinical and immunological effects of mRNA vaccines in malignant diseasesAnnkristin Heine, Stefan Juranek, Peter Brossart
Immunotherapy|July 20, 2010
Immunotherapy in renal cell carcinomaAnnkristin Heine, Tobias A W Holderried, Peter Brossart
Journal of Cancer Research and Clinical Oncology|June 22, 2022
Two cases of EBV infection preceding lymphomaJonas Saal, Busher Aboudan, Peter Brossart, et al.
Frontiers in Immunology|September 26, 2022
Red blood cell transfusions impact response rates to immunotherapy in patients with solid malignant tumorsRebekka Mispelbaum, Sandra Tessa Hattenhauer, Peter Brossart, et al.
Expert Review of Hematology|March 11, 2026
Longer time to response in hemato-oncological patients with immune thrombocytopenia (ITP): a pilot studyTessa Hattenhauer, Rebekka Mispelbaum, Peter Brossart, et al.
Journal of Biomedicine & Biotechnology|July 14, 2010
RNA vaccines in cancer treatmentAnita Bringmann, Stefanie Andrea Erika Held, Annkristin Heine, et al.
Pageof 7

Showing results (1-10 of 65) with videos related to

Sort By:
Pageof 7
Blood|May 30, 2015
A party of three: iNKT cells in GVHD preventionAnnkristin Heine, Peter Brossart
Experimental Hematology|March 31, 2025
Establishing a low-dose x-ray irradiation protocol for experimental acute graft-versus-host diseaseMichelle Klesse, Oliver Schanz, Annkristin Heine
Oncoimmunology|May 7, 2014
Implementing combinatorial immunotherapeutic regimens against cancer: The concept of immunological conditioningDominik Wolf, Annkristin Heine, Peter Brossart
Trends in Cancer|July 24, 2024
Next-generation cancer vaccines and emerging immunotherapy combinationsAnne Brandenburg, Annkristin Heine, Peter Brossart
Molecular Cancer|March 16, 2021
Clinical and immunological effects of mRNA vaccines in malignant diseasesAnnkristin Heine, Stefan Juranek, Peter Brossart
Immunotherapy|July 20, 2010
Immunotherapy in renal cell carcinomaAnnkristin Heine, Tobias A W Holderried, Peter Brossart
Journal of Cancer Research and Clinical Oncology|June 22, 2022
Two cases of EBV infection preceding lymphomaJonas Saal, Busher Aboudan, Peter Brossart, et al.
Frontiers in Immunology|September 26, 2022
Red blood cell transfusions impact response rates to immunotherapy in patients with solid malignant tumorsRebekka Mispelbaum, Sandra Tessa Hattenhauer, Peter Brossart, et al.
Expert Review of Hematology|March 11, 2026
Longer time to response in hemato-oncological patients with immune thrombocytopenia (ITP): a pilot studyTessa Hattenhauer, Rebekka Mispelbaum, Peter Brossart, et al.
Journal of Biomedicine & Biotechnology|July 14, 2010
RNA vaccines in cancer treatmentAnita Bringmann, Stefanie Andrea Erika Held, Annkristin Heine, et al.
Pageof 7